Related Experiment Videos
Multifocal inflammatory leukoencephalopathy developing in a patient receiving 5-fluorouracil and levamisole
P Critchley1, R Abbott, F J Madden
1Department of Neurology, Leicester Royal Infirmary NHS Trust, UK.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|January 1, 1994
Summary
A rare case of multifocal inflammatory leukoencephalopathy occurred during 5-fluorouracil (5FU) and levamisole chemotherapy. Subtle clinical signs may lead to this condition being frequently overlooked in patients.
Area of Science:
- Neurology
- Oncology
- Chemotherapy
Background:
- Adjuvant chemotherapy with 5-fluorouracil (5FU) and levamisole is a standard treatment for various cancers.
- Leukoencephalopathy is a rare but serious neurological complication associated with certain chemotherapeutic agents.
Observation:
- This report details a single case of multifocal inflammatory leukoencephalopathy.
- The condition developed in a patient undergoing adjuvant chemotherapy with 5FU and levamisole.
Findings:
- The neurological symptoms presented gradually and were not overtly dramatic.
- The slow onset of clinical features suggests a potential for underdiagnosis.
Implications:
- This case highlights the importance of considering leukoencephalopathy in patients receiving 5FU and levamisole chemotherapy, even with subtle symptoms.
- Increased awareness and vigilance are crucial for early detection and management of this adverse event.
- Further research may be warranted to understand the incidence and mechanisms of 5FU- and levamisole-induced leukoencephalopathy.